IDEXX Laboratories (IDXX) has recently seen significant growth, both in stock price and as a company. The firm's stock value moved above its 20-day moving average and reached an all-time high at 735.31 USD, spurred by strong Q3 earnings that outperformed estimates, leading to an increased full-year growth outlook. Financial guidance for 2025 has also been raised following strong Q3 results, which witnessed strong revenue growth and EPS. The company's future prospects appear promising, considering the fifteen percent surge in its stock following Q3 earnings and various recommendations and upgrades from investment firms including William Blair, Piper Sandler, BTIG, and Stifel. The company's potential undervaluation could present a profitable investment opportunity for long-term growth investors, and the firm's stock is reportedly outpacing the healthcare sector. Extraordinarily, over the last 10 years, owning IDEXX Laboratories stock has proven to be a highly lucrative investment. Even amid a bear market, the business has emerged stronger, once again highlighting its resilience.
Idexx Laboratories IDXX News Analytics from Mon, 26 May 2025 07:00:00 GMT to Sat, 22 Nov 2025 13:28:39 GMT - Rating 8 - Innovation 7 - Rumor 3
